## WHAT IS CLAIMED IS:

1. A method of inhibiting the growth of tumor cells in a tumor site of a subject, comprising administering to the tumor site an effective amount of an oligoaniline having the following formula:

wherein

m is an integer of 1-6;

n is an integer of 1-10;

each A is -H, -Z, $-CH_2-CO-OH$, $-CH_2-CO-O-Z$, $-CH_2-CO-S-Z$, $-CH_2-CO-NH_2$, or $-CH_2-CO-NH-Z$; and each X is -H, -O-Z, -S-Z, -NH-Z; Z being -E-D, wherein E is -R-, -R-Ar-, -Ar-R-, or -Ar-; and D is -OH, -SH, $-NH_2$, -NHOH, $-SO_3H$, $-OSO_3H$, $-CO_2H$, $-CONH_2$, $-CH(NH_2)-CO_2H$, $-P(OH)_3$, $-PO(OH)_2$, $-O-PO(OH)_2$, $-O-PO(OH)-O-PO(OH)_2$, $-O-PO(O^-)-O-CH_2CH_2NH_3^+$, -glycoside, $-OCH_3$, $-OCH_2(CHOH)_4-CH_2OH$, $-OCH_2(CHOH)_2-CH_2OH$, $-C_6H_3(OH)_2$, $-NH_3^+$, $-N^+H_2R_b$, $-N^+HR_bR_c$, or $-N^+R_bR_cR_d$, each of R, R_b, R_c, and R_d, independently, being C_{1-30} alkyl; and Ar being aryl;

W is -H, -CO-B, $-CH_2CH(OH)$-B, -CO-NH-B, -CS-NH-B, -CO-O-B, $CO-CH_2-CH(CO_2H)$-B, $-CH_2$-B, $-SO_2$-B, wherein B is $-R_1-O-[Si(CH_3)_2-O-]_{1-100}$, C_{1-2000} alkyl, C_{6-40} aryl, C_{7-60} alkylaryl, C_{7-60} arylalkyl, (C_{1-30} alkyl ether)$_{1-100}$, (C_{6-40} aryl ether)$_{1-100}$, (C_{7-60} alkylaryl ether)$_{1-100}$, (C_{7-60} arylalkyl ether)$_{1-100}$, (C_{1-30} alkyl thioether)$_{1-100}$, (C_{6-40} aryl thioether)$_{1-100}$, (C_{7-60} alkylaryl thioether)$_{1-100}$, (C_{7-60} arylalkyl thioether)$_{1-100}$, (C_{2-50} alkyl ester)$_{1-100}$, (C_{7-60} aryl ester)$_{1-100}$, (C_{8-70} alkylaryl ester)$_{1-100}$, (C_{8-70} arylalkyl ester)$_{1-100}$, $-R_1-CO-O-(C_{1-30}$ alkyl ether)$_{1-100}$, $-R_1-CO-O-(C_{6-40}$ aryl ether)$_{1-100}$, $-R_1-CO-O-(C_{7-60}$ alkylaryl ether)$_{1-100}$, $-R_1-CO-O-(C_{7-60}$ arylalkyl ether)$_{1-100}$, (C_{4-50} alkyl urethane)$_{1-100}$, (C_{14-60} aryl urethane)$_{1-100}$, (C_{10-80} alkylaryl urethane)$_{1-100}$, (C_{10-80} arylalkyl urethane)$_{1-100}$, (C_{5-50} alkyl urea)$_{1-100}$, (C_{14-60} aryl urea)$_{1-100}$, (C_{10-80} alkylaryl urea)$_{1-100}$, (C_{10-80} arylalkyl urea)$_{1-100}$, (C_{2-50} alkyl amide)$_{1-100}$, (C_{7-60} aryl amide)$_{1-100}$, (C_{8-70} alkylaryl amide)$_{1-100}$, (C_{8-70} arylalkyl amide)$_{1-100}$, (C_{3-30} alkyl anhydride)$_{1-100}$, (C_{8-50} aryl anhydride)$_{1-100}$, (C_{9-60}

alkylaryl anhydride)$_{1-100}$, (C$_{9-60}$ arylalkyl anhydride)$_{1-100}$, (C$_{2-30}$ alkyl carbonate)$_{1-100}$,

(C$_{7-50}$ aryl carbonate)$_{1-100}$, (C$_{8-60}$ alkylaryl carbonate)$_{1-100}$, (C$_{8-60}$ arylalkyl carbonate)$_{1-100}$,

-R$_1$-O-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-(C$_{1-30}$ alkyl ether, C$_{6-40}$ aryl ether, C$_{7-60}$

alkylaryl ether, or C$_{7-60}$ arylalkyl ether)$_{1-100}$, -R$_1$-O-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-

(C$_{2-50}$ alkyl ester, C$_{7-60}$ aryl ester, C$_{8-70}$ alkylaryl ester, or C$_{8-70}$ arylalkyl ester)$_{1-100}$, -R$_1$-O-

CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-(C$_{1-30}$ alkyl ether, C$_{6-40}$ aryl ether, C$_{7-60}$ alkylaryl

ether, or C$_{7-60}$ arylalkyl ether)$_{1-100}$-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-, -R$_1$-O-CO-NH-

(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-(C$_{2-50}$ alkyl ester, C$_{7-60}$ aryl ester, C$_{8-70}$ alkylaryl ester, or

C$_{8-70}$ arylalkyl ester)$_{1-100}$-R$_3$-O-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-, -R$_1$-NH-CO-NH-

(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-(C$_{1-30}$ alkyl ether, C$_{6-40}$ aryl ether, C$_{7-60}$ alkylaryl ether, or

C$_{7-60}$ arylalkyl ether)$_{1-100}$, -R$_1$-NH-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-(C$_{2-50}$ alkyl ester,

C$_{7-60}$ aryl ester, C$_{8-70}$ alkylaryl ester, or C$_{8-70}$ arylalkyl ester)$_{1-100}$, -R$_1$-NH-CO-NH-(R$_2$ or

Ar-R$_2$-Ar)-NH-CO-O-(C$_{1-30}$ alkyl ether, C$_{6-40}$ aryl ether, C$_{7-60}$ alkylaryl ether, or C$_{7-60}$

arylalkyl ether)$_{1-100}$-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-, -R$_1$-NH-CO-NH-(R$_2$ or Ar-

R$_2$-Ar)-NH-CO-O-(C$_{2-50}$ alkyl ester, C$_{7-60}$ aryl ester, C$_{8-70}$ alkylaryl ester, or C$_{8-70}$

arylalkyl ester)$_{1-100}$-R$_3$O-CO-NH-(R$_2$ or Ar--R$_2$-Ar)-NH-CO-O-, -R$_1$-O-CO-NH-(R$_2$ or

Ar-R$_2$-Ar)-NH-CO-NH-(C$_{2-50}$ alkyl amide, C$_{7-60}$ aryl amide, C$_{8-70}$ alkylaryl amide, or

C$_{8-70}$ arylalkyl amide)$_{1-100}$, or -R$_1$-NH-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-NH-(C$_{2-50}$ alkyl

amide, C$_{7-60}$ aryl amide, C$_{8-70}$ alkylaryl amide, or C$_{8-70}$ arylalkyl amide)$_{1-100}$; wherein each

of R$_1$, R$_2$, and R$_3$, independently, is C$_{1-30}$ alkyl; and Ar is aryl;

K is -H, -[N(X)-C$_6$H$_4$]$_{1-3}$-NH$_2$, -[N(X)-C$_6$H$_4$]$_{1-3}$-NH-C(=S)-SH, -[N(X)-C$_6$H$_4$]$_{1-3}$-

N=CH-Ar-SH, or -[N(X)-C$_6$H$_4$]$_{1-3}$-NH-CO-Ar-SH, wherein X is -H, -Z, -CH$_2$-CO-OH,

-CH$_2$-CO-O-Z, -CH$_2$-CO-S-Z, -CH$_2$-CO-NH$_2$ or -CH$_2$-CO-NH-Z; and Ar is aryl;

and subsequently exposing the tumor site to irradiation.

2. The method of claim 1, wherein A is -Z, -CH$_2$-CO-O-Z, -CH$_2$-CO-S-Z, or -CH$_2$-CO-NH-

Z; wherein E is -R- or -R-Ar-; and D is -OH, -SH, -NH$_2$, -NHOH, -SO$_3$H, -OSO$_3$H,

-CO$_2$H, -CONH$_2$, -CH(NH$_2$)-CO$_2$H, -P(OH)$_3$, -PO(OH)$_2$, -O-PO(OH)$_2$, -O-PO(OH)-O-

PO(OH)$_2$, or -NH$_3^+$.

3. The method of claim 1, wherein m is an integer of 2-6.

4. The method of claim 1, wherein n is an integer of 1-6.

5. The method of claim 2, wherein A is -Z, Z being -E-D, wherein E is -R-, or -R-Ar-; and D is -OH, -SH, -NH$_2$, -NHOH, -SO$_3$H, -OSO$_3$H, -CO$_2$H, -CONH$_2$, -P(OH)$_3$, -PO(OH)$_2$, -O-PO(OH)$_2$, -O-PO(OH)-O-PO(OH)$_2$, or -NH$_3^+$.

6. The method of claim 2, wherein n is an integer of 1-6.

7. The method of claim 2, wherein m is an integer of 2-6.

8. The method of claim 6, wherein m is an integer of 2-6.

9. The method of claim 5, wherein E is -R-; and D is -SO$_3$H, -OSO$_3$H, -CO$_2$H, -O-PO(OH)$_2$, or -O-PO(OH)-O-PO(OH)$_2$.

10. The method of claim 5, wherein m is an integer of 2-6.

11. The method of claim 5, wherein n is an integer of 1-6.

12. The method of claim 9, wherein E is -C$_3$H$_6$-; D is -SO$_3$H; n is an integer of 1-6; and m is an integer of 2-6.

13. The method of claim 12, wherein m is 4.

14. The method of claim 13, wherein each of W, X, and K is H.

15. The method of claim 3, wherein m is 4.

16. The method of claim 3, wherein n is an integer of 1-6.

17. The method of claim 15, wherein n is an integer of 1-6.

18. A pharmaceutical composition for inhibiting the growth of tumor cells, comprising a compound of the following formula:

$$W-\left[\left(N-\underset{\underset{A}{|}}{\overset{}{}}\underset{m}{\bigodot^{X}}\right)K\right]_n$$

wherein

m is an integer of 1-6;

n is an integer of 1-10;

each A is -H, -Z, -CH$_2$-CO-OH, -CH$_2$-CO-O-Z, -CH$_2$-CO-S-Z, -CH$_2$-CO-NH$_2$, or -CH$_2$-CO-NH-Z; and each X is -H, -O-Z, -S-Z, -NH-Z; Z being -E-D, wherein E is -R-, -R-Ar-, -Ar-R-, or -Ar- and D is -OH, -SH, -NH$_2$, -NHOH, -SO$_3$H, -OSO$_3$H, -CO$_2$H, -CONH$_2$, -CH(NH$_2$)-CO$_2$H, -P(OH)$_3$, -PO(OH)$_2$, -O-PO(OH)$_2$, -O-PO(OH)-O-PO(OH)$_2$, -O-PO(O$^-$)-O-CH$_2$CH$_2$NH$_3^+$, -glycoside, -OCH$_3$, -OCH$_2$(CHOH)$_4$-CH$_2$OH, -OCH$_2$(CHOH)$_2$-CH$_2$OH, -C$_6$H$_3$(OH)$_2$, -NH$_3^+$, -N$^+$H$_2$R$_b$, -N$^+$HR$_b$R$_c$, or -N$^+$R$_b$R$_c$R$_d$, each of R, R$_b$, R$_c$, and R$_d$, independently, being C$_{1-30}$ alkyl; and Ar being aryl;

W is -H, -CO-B, -CH$_2$CH(OH)-B, -CO-NH-B, -CS-NH-B, -CO-O-B, CO-CH$_2$-CH(CO$_2$H)-B, -CH$_2$-B, -SO$_2$-B, wherein B is -R$_1$-O-[Si(CH$_3$)$_2$-O-]$_{1-100}$, C$_{1-2000}$ alkyl, C$_{6-40}$ aryl, C$_{7-60}$ alkylaryl, C$_{7-60}$ arylalkyl, (C$_{1-30}$ alkyl ether)$_{1-100}$, (C$_{6-40}$ aryl ether)$_{1-100}$, (C$_{7-60}$ alkylaryl ether)$_{1-100}$, (C$_{7-60}$ arylalkyl ether)$_{1-100}$, (C$_{1-30}$ alkyl thioether)$_{1-100}$, (C$_{6-40}$ aryl thioether)$_{1-100}$, (C$_{7-60}$ alkylaryl thioether)$_{1-100}$, (C$_{7-60}$ arylalkyl thioether)$_{1-100}$, (C$_{2-50}$ alkyl ester)$_{1-100}$, (C$_{7-60}$ aryl ester)$_{1-100}$, (C$_{8-70}$ alkylaryl ester)$_{1-100}$, (C$_{8-70}$ arylalkyl ester)$_{1-100}$, -R$_1$-CO-O-(C$_{1-30}$ alkyl ether)$_{1-100}$, -R$_1$-CO-O-(C$_{6-40}$ aryl ether)$_{1-100}$, -R$_1$-CO-O-(C$_{7-60}$ alkylaryl ether)$_{1-100}$, -R$_1$-CO-O-(C$_{7-60}$ arylalkyl ether)$_{1-100}$, (C$_{4-50}$ alkyl urethane)$_{1-100}$, (C$_{14-60}$ aryl urethane)$_{1-100}$, (C$_{10-80}$ alkylaryl urethane)$_{1-100}$, (C$_{10-80}$ arylalkyl urethane)$_{1-100}$, (C$_{5-50}$ alkyl urea)$_{1-100}$, (C$_{14-60}$ aryl urea)$_{1-100}$, (C$_{10-80}$ alkylaryl urea)$_{1-100}$, (C$_{10-80}$ arylalkyl urea)$_{1-100}$, (C$_{2-50}$ alkyl amide)$_{1-100}$, (C$_{7-60}$ aryl amide)$_{1-100}$, (C$_{8-70}$ alkylaryl amide)$_{1-100}$, (C$_{8-70}$ arylalkyl amide)$_{1-100}$, (C$_{3-30}$ alkyl anhydride)$_{1-100}$, (C$_{8-50}$ aryl anhydride)$_{1-100}$, (C$_{9-60}$ alkylaryl anhydride)$_{1-100}$, (C$_{9-60}$ arylalkyl anhydride)$_{1-100}$, (C$_{2-30}$ alkyl carbonate)$_{1-100}$, (C$_{7-50}$ aryl

carbonate)$_{1-100}$, (C$_{8-60}$ alkylaryl carbonate)$_{1-100}$, (C$_{8-60}$ arylalkyl carbonate)$_{1-100}$, -R$_1$-O-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-(C$_{1-30}$ alkyl ether, C$_{6-40}$ aryl ether, C$_{7-60}$ alkylaryl ether, or C$_{7-60}$ arylalkyl ether)$_{1-100}$, -R$_1$-O-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-(C$_{2-50}$ alkyl ester, C$_{7-60}$ aryl ester, C$_{8-70}$ alkylaryl ester, or C$_{8-70}$ arylalkyl ester)$_{1-100}$, -R$_1$-O-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-(C$_{1-30}$ alkyl ether, C$_{6-40}$ aryl ether, C$_{7-60}$ alkylaryl ether, or C$_{7-60}$ arylalkyl ether)$_{1-100}$-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-, -R$_1$-O-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-(C$_{2-50}$ alkyl ester, C$_{7-60}$ aryl ester, C$_{8-70}$ alkylaryl ester, or C$_{8-70}$ arylalkyl ester)$_{1-100}$-R$_3$-O-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-, -R$_1$-NH-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-(C$_{1-30}$ alkyl ether, C$_{6-40}$ aryl ether, C$_{7-60}$ alkylaryl ether, or C$_{7-60}$ arylalkyl ether)$_{1-100}$, -R$_1$-NH-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-(C$_{2-50}$ alkyl ester, C$_{7-60}$ aryl ester, C$_{8-70}$ alkylaryl ester, or C$_{8-70}$ arylalkyl ester)$_{1-100}$, -R$_1$-NH-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-(C$_{1-30}$ alkyl ether, C$_{6-40}$ aryl ether, C$_{7-60}$ alkylaryl ether, or C$_{7-60}$ arylalkyl ether)$_{1-100}$-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-, -R$_1$-NH-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-O-(C$_{2-50}$ alkyl ester, C$_{7-60}$ aryl ester, C$_{8-70}$ alkylaryl ester, or C$_{8-70}$ arylalkyl ester)$_{1-100}$-R$_3$O-CO-NH-(R$_2$ or Ar--R$_2$-Ar)-NH-CO-O-, -R$_1$-O-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-NH-(C$_{2-50}$ alkyl amide, C$_{7-60}$ aryl amide, C$_{8-70}$ alkylaryl amide, or C$_{8-70}$ arylalkyl amide)$_{1-100}$, or -R$_1$-NH-CO-NH-(R$_2$ or Ar-R$_2$-Ar)-NH-CO-NH-(C$_{2-50}$ alkyl amide, C$_{7-60}$ aryl amide, C$_{8-70}$ alkylaryl amide, or C$_{8-70}$ arylalkyl amide)$_{1-100}$; wherein each of R$_1$, R$_2$, and R$_3$, independently, is C$_{1-30}$ alkyl; and Ar is aryl;

K is -H, -[N(X)-C$_6$H$_4$]$_{1-3}$-NH$_2$, -[N(X)-C$_6$H$_4$]$_{1-3}$-NH-C(=S)-SH, -[N(X)-C$_6$H$_4$]$_{1-3}$-N=CH-Ar-SH, or -[N(X)-C$_6$H$_4$]$_{1-3}$-NH-CO-Ar-SH, wherein X is -H, -Z, -CH$_2$-CO-OH, -CH$_2$-CO-O-Z, -CH$_2$-CO-S-Z, -CH$_2$-CO-NH$_2$ or -CH$_2$-CO-NH-Z; and Ar is aryl; and

a pharmaceutically acceptable carrier

19. The pharmaceutical composition of claim 18, wherein A is -Z, -CH$_2$-CO-O-Z, -CH$_2$-CO-S-Z, or -CH$_2$-CO-NH-Z; E is -R- or -R-Ar-; and D is -OH, -SH, -NH$_2$, -NHOH, -SO$_3$H, -OSO$_3$H, -CO$_2$H, -CONH$_2$, -CH(NH$_2$)-CO$_2$H, -P(OH)$_3$, -PO(OH)$_2$, -O-PO(OH)$_2$, -O-PO(OH)-O-PO(OH)$_2$, or -NH$_3^+$.

20. The pharmaceutical composition of claim 19, wherein A is -Z; E is -R-; and D is -SO_3H, -OSO_3H, -CO_2H, -$CH(NH_2)$-CO_2H, -$P(OH)_3$, -$PO(OH)_2$, -O-$PO(OH)_2$, or -O-PO(OH)-O-$PO(OH)_2$.

21. The pharmaceutical composition of claim 20, wherein E is -C_3H_6-; D is -SO_3H; n is an integer of 1-6; m is an integer of 2-6; and each of W, X, and K is H.